

OPINION

Axis of ageing: telomeres, p53 and mitochondria

Ergün Sahin and Ronald A. DePinho

Abstract | Progressive DNA damage and mitochondrial decline are both considered to be prime instigators of natural ageing. Traditionally, these two pathways have been viewed largely in isolation. However, recent studies have revealed a molecular circuit that directly links DNA damage to compromised mitochondrial biogenesis and function via p53. This axis of ageing may account for both organ decline and disease development associated with advanced age and could illuminate a path for the development of relevant therapeutics.

Ageing and its inevitable companions — disease and death — have fascinated mankind for millennia and have spurred the search for eternal youth. Long believed to be unchangeable, life expectancy and ‘healthspan’ have increased dramatically over the past two centuries. This has been fuelled by advances in medical science, improved hygiene and nutrition, and significant declines in mortality rates among the young¹.

Now, the question is: can lifespan be further increased, or have we reached a biologically determined maximum lifespan? Scientists have long tried to identify pathways that are relevant for ageing, but it was not until the 1990s that the first genetic foothold was established in ageing: a loss-of-function mutation in *daf-2* (which encodes an insulin/insulin-like growth factor 1 (IGF1)-like receptor) doubled the lifespan of worms². Since then, the interest in the molecular pathways that control ageing has exploded, and many more mutations in metabolic pathways have been shown to affect lifespan in different model systems, ranging from yeast to mice³. Studies suggest that these pathways are also relevant for human lifespan, but how they might extend lifespan is not entirely clear^{4,5}. However, among others, maintenance of mitochondrial function has been suggested to be an important mechanism of extending lifespan, as decreased mitochondrial function, impaired ATP generation and increased reactive oxygen species (ROS)

levels have been implicated in driving the ageing process⁶.

In addition to the role of metabolic pathways, telomere maintenance has been shown to be linked to ageing⁷. Cultured human fibroblasts divide a finite number of times before entering a non-dividing state called senescence⁸. Subsequent work established that the ends of chromosomes, or telomeres, became shorter with each round of replication. These observations fuelled speculation that the loss of telomeres represents a type of molecular clock that drives ageing^{9–12}. These studies underscored the general importance of DNA integrity, as dysfunctional telomeres are recognized as DNA damage and activate the DNA damage response pathway, which leads to the activation of p53 (REFS 13,14). p53, in turn, induces growth arrest, apoptosis and senescence in stem and progenitor cells^{15–18}.

“ a model of how different pathways ... intersect and converge on mitochondria ”

Recent studies have uncovered additional mechanistic insights into telomere-mediated ageing, in which telomere shortening and associated DNA damage responses promote mitochondrial dysfunction, diminished oxidative defence and compromised energy-generating processes. This general decline in

energy maintenance could account for the decline seen in stem and progenitor cells as well as in post-mitotic tissues¹⁹.

In this Opinion article we present a model of how different pathways — DNA damage and metabolic pathways — intersect and converge on mitochondria to compromise energy maintenance and drive ageing. This integrated view provides a better understanding of the mechanisms that control the fundamental process of ageing and may open new avenues for therapeutic interventions for ageing and age-associated diseases.

Metabolic pathways in ageing

Several metabolic pathways and molecules regulate lifespan in response to nutrient availability and balance energy expenditure with mitochondrial function (BOX 1; FIG. 1). The insulin and IGF1 pathway was the first evolutionarily conserved pathway shown to regulate lifespan. Mammalian target of rapamycin (mTOR) signalling has also been implicated^{3,20} (BOX 1). There is increasing recognition that these metabolic pathways are intimately interconnected. For instance, AMP-activated protein kinase (AMPK), which is a central sensor of energy homeostasis that modulates mTOR signalling, activates forkhead box O (FOXO) transcription factors, which are targets of insulin and IGF1 signalling. This increases the expression of genes that are involved in stress resistance and energy balance²¹. AMPK also activates PPAR γ co-activator 1 α (PGC1 α), which is a central regulator of mitochondrial biogenesis and function. Similarly, AMPK induces sirtuin 1 (SIRT1), which activates PGC1 α and FOXO transcription factors²². There is also a close relationship between FOXO proteins and PGC1 α , as FOXO1 and FOXO3 have been shown to increase PGC1 α activity, and PGC1 α itself can augment the transcriptional activity of FOXO3 (REFS 23–25). SIRT1 also inactivates the ‘guardian of the genome’, p53 (REFS 26,27). p53 itself intersects with several different longevity pathways, including insulin and IGF1, mTOR and AMPK²⁸. The activation of AMPK and the repression of the insulin and IGF1 pathway and the mTOR pathway by p53 demonstrate the ability of p53 to positively regulate pathways that are essential for cell integrity and longevity²⁸.


Box 1 | Metabolic pathways and genes implicated in lifespan regulation

Evolutionary conserved insulin and IGF1 signalling pathway

The insulin and insulin-like growth factor 1 (IGF1) pathway was the first evolutionarily conserved pathway shown to regulate lifespan in *Caenorhabditis elegans*. Components of this pathway include phosphoinositide 3-kinase (PI3K; AGE-1 in *C. elegans*), 3'-phosphoinositide-dependent kinase 1 (PDK-1), AKT (also known as PKB) and forkhead box O (FOXO) family transcription factors (DAF-16 in *C. elegans*). In response to insulin and IGF-1, PI3K activates PDK-1, which in turn activates AKT. AKT phosphorylates multiple downstream targets to promote cell survival and cell growth (see the figure, part a). Decreased activity of the insulin and IGF-1 pathway owing to loss-of-function mutations in genes that encode key components of this pathway or proteins that regulate its activity, such as growth hormones, extends lifespan in many species. The lifespan extension effect in these mutants is mediated by several transcription factors and their transcriptional targets, including DAF-16, heat shock factor 1 (HSF-1) and SKN-1 (a transcription factor involved in the oxidative stress response), which stimulate the expression of genes that increase stress resistance, oxidative defence and mitochondrial function³.

mTOR signalling

Mammalian target of rapamycin (mTOR) is an evolutionarily conserved protein kinase that exists in two complexes, mTORC1 (see the figure, part b) and mTORC2 (not shown). mTORC2 is involved in cytoskeletal remodelling, whereas mTORC1 is a potent regulator of cellular growth and lifespan. mTORC1 activates the ribosomal protein S6 kinase (S6K) and inhibits eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1; a negative regulator of translation) to stimulate translation and cell growth¹³⁷. Inhibition of mTOR through caloric restriction, rapamycin treatment or genetic means extends lifespan in species ranging from yeast to mice²⁹. Similarly, inhibiting S6K increases lifespan in worms and flies, and female mice lacking S6K have prolonged lifespan and are protected from age-related pathologies such as insulin resistance, immunological decline and motor dysfunction^{3,29}. Lifespan extension in these S6K-deficient mice seems to be mediated by AMP-activated protein kinase (AMPK), which is a central sensor of energy homeostasis³⁶. AMPK is potentially activated by an increased AMP/ATP ratio, turns off anabolic pathways through indirect inhibition of mTORC1 and switches on catabolic pathways to generate ATP under energy stress. AMPK increases ATP levels by stimulating mitochondrial biogenesis and function, as well as fatty acid oxidation, among others¹³⁸. Activation of AMPK in mice with metformin (an antidiabetic drug) enhances lifespan, and deletion of the AMPK orthologue *aak-2* in *C. elegans* abrogates the lifespan extension induced in *daf-2* mutants, which supports the notion that the regulation of energy pathways and preservation of mitochondrial function is integral to longevity^{3,29}.



How these pathways, alone or in combination, regulate lifespan is being extensively investigated, and many different mechanisms seem to be involved^{13,29}. Among these, mitochondrial function and ROS defence are considered to be important modulators of lifespan. Along these lines, decreased activity of the insulin and IGF1 pathway is associated with improved mitochondrial function, as demonstrated in long-lived Ames mice (which have very low levels of IGF1) and in mice with decreased levels of insulin receptor substrate 2 (IRS2)^{30,31}. Reduced insulin and IGF1 signalling results in the activation of FOXO transcription factors, which induce

the expression of antioxidants, such as manganese superoxide dismutase (MnSOD) and catalase; accordingly, FOXO-deficient mice display increased levels of ROS and stem cell depletion³²⁻³⁴. Decreased mTOR activity during dietary restriction is also associated with improved mitochondrial function, and lifespan extension in this model depends on increased levels of respiration³⁵. Furthermore, mice lacking S6 kinase (S6K), which is a downstream component of mTOR signalling, are long lived and show increased oxidative phosphorylation (OXPHOS) and oxygen consumption³⁶. AMPK enhances SIRT1 activity (through increased NAD⁺ levels)

and this, in turn, stimulates PGC1 α and subsequently increases levels of OXPHOS and mitochondrial biogenesis³⁷.

Further evidence for an essential and direct role of the maintenance of mitochondrial function in lifespan comes from mice expressing a proofreading-deficient mitochondrial DNA polymerase- γ (Poly) variant that causes a premature ageing syndrome with shortened lifespan (the 'mutator mice')^{38,39}. Overexpression of the antioxidant enzyme catalase specifically in mitochondria reduces ROS-induced damage and significantly improves age-related cardiac decline in both wild-type and mutator mice^{40,41}. However, many other ROS-related studies have yielded conflicting results and question the role of increased ROS levels for the ageing process^{42,43}. Subjecting mutator mice to continuous exercise potentially rescues the premature ageing phenotype, which indicates that mitochondrial biogenesis and turnover (both of which are quality control mechanisms) are important for slowing down the ageing process in these mice⁴⁴.

Although these studies indicate that mitochondrial decline drives ageing, other studies show a more complex picture, as mild impairment of mitochondrial function can extend lifespan in yeast, worms and mice^{3,45-49}. This dichotomous role of mitochondria in lifespan has also been noted with other molecules that are involved in ageing, including p53 and AMPK⁵⁰⁻⁵². Thus, a more detailed view of how these key molecules are tightly regulated in the context of mitochondrial biology is required to optimally control the molecular circuitry of ageing.

Telomeres and ageing

A separate line of extensive research has implicated telomere integrity as a major regulator of longevity^{53,54}. Telomeres are repetitive TTAGGG sequences that cap chromosomes and prevent the ends from being recognized as DNA damage⁵⁵. Most human cells lack adequate levels of telomerase to maintain telomeres, and this results in telomere shortening with each round of replication^{9,11,56}. The importance of telomere length in ageing was initially inferred from seminal studies carried out in primary human fibroblasts in the early 1960s by Hayflick and Moorhead⁸. These cells divide a finite number of times *in vitro* and undergo telomere shortening with continuous passaging and, eventually, senescence⁸. Telomerase reactivation elongates telomeres and allows fibroblasts to bypass senescence and grow indefinitely, which demonstrates the causal role of shortened telomeres in cellular ageing⁵⁷.

Indeed, telomere length has been shown to gradually decline with age in many human tissues, including proliferative compartments and more quiescent tissues^{11,58–60}. Interestingly, even cells that express telomerase undergo telomere shortening over time, which points towards a complex regulation of telomere length⁶¹. Moreover, many studies have found a positive correlation between telomere shortening in human peripheral leukocytes and the risk of typical age-associated diseases⁶².

Further support for the role of telomeres in ageing comes from patients with loss-of-function mutations in genes that are crucial for telomere length maintenance, as these mutations predispose individuals to accelerated ageing. Mutations in TERC (the RNA component of telomerase) and TERT (the catalytic component of telomerase) are found in patients with the premature ageing syndrome dyskeratosis congenita⁶³. Mutations in the genes encoding Werner syndrome ATP-dependent helicase (WRN) and ataxia telangiectasia mutated (ATM) cause Werner syndrome and the neurodegenerative disorder ataxia telangiectasia, respectively⁶⁴. In addition to these multisystem disorders, TERC and TERT loss-of-function mutations are associated with the development of more organ-restricted diseases such as liver fibrosis, idiopathic pulmonary fibrosis and bone marrow failure syndromes⁶³. The manifestation of degenerative phenotypes in telomere maintenance conditions depends on the degree of telomere dysfunction, as evidenced by the earlier and more severe occurrence of pathologies in subsequent generations of patients with dyskeratosis congenita, who have shorter telomeres (known as the anticipation effect)⁶⁵. Although these studies of telomere maintenance disorders have provided evidence for the importance of telomeres for organ integrity and lifespan regulation, some pathologies seen in these patients are not typically observed during normal ageing and caution against a simple extrapolation of these findings to normal ageing. The exacerbated phenotypes in these patients might relate to excessive telomere shortening beyond what is seen in many proliferative and more static tissues during normal ageing in humans and may also be driven by environmental factors.

A link between telomeres and ageing has also been obtained from studies in mice. There is increasing recognition that telomere length and integrity are compromised during ageing in wild-type mice^{66,67}. Interestingly, the presence of one or a few




Figure 1 | **Proposed causes of ageing.** Major cellular pathways are implicated in the ageing process. Increased DNA damage, p53 and p16 activity and mitochondrial dysfunction have been shown to promote functional decline and ageing. By contrast, decreased activity in the mammalian target of rapamycin (mTOR), S6 kinase (S6K) and the insulin and insulin-like growth factor 1 (IGF1) pathways increase lifespan in different organisms.

dysfunctional telomeres in cells seems to be sufficient to trigger a DNA damage response, and this could underline the development of pathologies^{68,69}. Accordingly, overexpression of telomerase can delay some age-associated changes in mice that have been engineered to be resistant to cancer⁷⁰. Furthermore, the role of telomeres for organismal fitness and lifespan has been substantiated in mice lacking telomerase activity, which develop numerous age-associated degenerative phenotypes once their telomeres become short and die prematurely^{71,72}. Moreover, mouse models of Werner syndrome and ataxia telangiectasia develop classical human-like pathologies only when their telomeres are short, which demonstrates the essential role of critically short telomeres in disease manifestation^{16,73,74}. Finally, telomerase overexpression can reverse age-associated decline in multiple tissues in mice with established degenerative phenotypes⁷⁵.

These studies indicate that telomere dysfunction can drive the functional decline of tissues, promote ageing and shorten lifespan and, importantly, that the ageing process can be prevented or even be reversed by telomerase reactivation. However, it is clear that currently there is only an elemental understanding of the precise role of telomeres in natural ageing and how telomeres might influence age-associated pathologies.

Telomere–mitochondrion connection

How do waning telomeres precipitate such widespread degeneration? One clue comes from the observation that patients with dyskeratosis congenita, Werner syndrome and ataxia telangiectasia, and mice with dysfunctional telomeres, develop organ failure particularly in highly proliferative organs such as the intestines, skin and bone marrow^{76–78}. These organs rely on continuous regeneration, which is mediated by resident stem and progenitor cells. This observation has led to the hypothesis that telomere-based ageing is primarily a

stem cell defect caused by the activation of p53 and the induction of growth arrest, senescence and apoptosis in these cellular compartments⁷⁹. Indeed, telomere shortening is accompanied by increased p53 activity in these cells and, consequently, high levels of apoptosis^{15,18}. Mice lacking p53 or its downstream targets show functional rescue of stem and progenitor cells in the haematopoietic system, skin and gastrointestinal tract, as well as concomitant rescue of tissue pathologies^{15,18,80}. Although the stem cell theory of ageing helps to rationalize the failure of highly regenerative tissues, it does not readily explain age-dependent changes in more quiescent tissues that dependent less on stem and progenitor cell activity for tissue homeostasis.

Indeed, general metabolic disorders and functional decline in mostly post-mitotic tissues such as the heart, liver and pancreas are well-recognized features in the aged, in patients with telomere maintenance disorders and in telomere-dysfunctional mice^{65,81}. For instance, individuals with dyskeratosis congenita, Werner syndrome and ataxia telangiectasia are prone to develop insulin resistance and diabetes^{65,82,83}. Moreover, cardiomyopathy has been recognized in patients with dyskeratosis congenita, in telomere-dysfunctional mice and in mouse models of ataxia telangiectasia^{81,84,85}. Liver fibrosis and pulmonary fibrosis represent other pathophysiological manifestations in patients with dyskeratosis congenita. Hepatic toxicity is a major side effect in patients with dyskeratosis congenita, who receive cytotoxic chemotherapy for aplastic anaemia-related bone marrow transplantation⁶⁵. Quiescent tissues such as the heart and liver have also been reported to undergo age-dependent telomere shortening, the basis for which is unclear^{58,60}. Together, these observations suggest additional mechanisms of telomere-induced ageing beyond traditional p53-dependent checkpoint responses of apoptosis and senescence.




Figure 2 | Telomere–p53–PGC pathway. p53 induced by telomere dysfunction binds to the promoters of PPAR γ co-activator 1 α (PGC1 α) and PGC1 β and represses the expression of PGC1A and PGC1B. The repression of both co-activators impairs overall mitochondrial biogenesis and function and leads to defective ATP generation and increased levels of reactive oxygen species (ROS). PGCs are also involved in energy metabolism by regulating different biochemical pathways such as fatty acid oxidation, gluconeogenesis, glucose uptake and oxidation. The compromise in mitochondrial function and other biochemical pathways might equally lead to functional decline in tissue stem cells and post-mitotic tissues and drive ageing. Telomerase reactivation or PGC overexpression can reverse PGC-associated metabolic and mitochondrial changes in mice with established telomere dysfunction. Telomere dysfunction may also lead to compromised mitochondrial function and energy metabolism through other pathways (dashed arrows).

Some clues for additional mechanisms have surfaced from recent work in TERT-deficient mice with telomere dysfunction. This study reported a marked compromise in mitochondrial biogenesis and function in diverse tissues, including liver, heart and haematopoietic stem cells, which raises the possibility that a fundamental problem in energy maintenance might contribute to the premature ageing phenotypes in these mice¹⁹. These marked mitochondrial changes seem to be caused by the combined suppression of the transcriptional co-activators PGC1 α and PGC1 β and their downstream targets (FIG. 2). This is mediated by direct binding of p53 to the promoters of PGC1 α and PGC1 β ; accordingly, telomere-dysfunctional mice lacking p53 have normal PGC expression, increased mitochondrial DNA (mtDNA) content, improved gluconeogenesis and blunted doxorubicin-induced cardiomyopathy. In line with the important role of PGCs in regulating diverse processes, TERT-deficient mice show reduced expression of genes that are essential for gluconeogenesis, β -oxidation and ROS defence, and they have greatly compromised OXPHOS, with reduced ATP generation, impaired gluconeogenic capacity and age-dependent cardiomyopathy. Of note, these changes are more pronounced with increasing telomere

dysfunction. Importantly, overexpression of TERT or PGC1 α in mice with telomere dysfunction improves mitochondrial respiration and gluconeogenesis, which confirms that the phenotype of TERT-deficient mice is caused by PGC suppression¹⁹. This telomere-mitochondrion link is also suggested by other studies, including those demonstrating increased ROS levels and mitochondrial dysfunction in cultured human fibroblasts, in fibroblasts overexpressing a mutant form of TERT and in heart tissues of TERT-deficient mice^{86–88}. The basis for these defects has been suggested to be secondary to the activation of the p21–transforming growth factor- β (TGF β)–p53 pathways and increased mtDNA damage^{86–88}. Moreover, a recent study found reduced mitochondrial membrane hyperpolarization and impaired Ca²⁺ influx in telomere-dysfunctional mice, which leads to reduced insulin release in β -cells⁸⁹.

Previous studies have suggested that TERT has telomere elongation-independent functions^{90–94}. However, TERC-deficient mice, which lack telomerase activity but have intact TERT expression, showed similar robust changes centred on PGC and mitochondrial suppression, which indicates that telomere dysfunction is the determining factor driving these changes¹⁹. Moreover, TERT- and TERC-knockout mice have indistinguishable

phenotypes and similar transcriptomic profiles⁹⁵. That said, these genetic studies were not designed to rigorously exclude more subtle telomere-independent roles of TERT. Indeed, continued study is warranted, as TERT has been shown to localize to mitochondria, retain reverse transcriptase activity, carry out different mitochondrial functions (such as modulating mtDNA integrity, improving respiratory chain function and affecting ROS production) and to potentially activate other pathways such as the WNT pathway (although this has been questioned recently)^{88,96–100}.

Furthermore, aged tissues often demonstrate concomitant telomere dysfunction, increased DNA damage and p53 activity as well as reduced PGC levels and mitochondrial function⁷. Importantly, studies in cells derived from patients and mouse models corroborate this link between telomeres and mitochondria^{101–103}. For example, cells derived from patients with Werner syndrome have compromised mitochondrial function and increased ROS levels¹⁰³. Although these observations support the importance of the telomere–p53–mitochondrion axis of ageing, more work is required to assess whether mitochondrial biogenesis and function are consistently impaired in human telomere-shortening conditions.

An integrated view of ageing

The connection between telomeres and mitochondria supports a model for ageing whereby DNA damage-induced p53 activation leads to mitochondrial dysfunction through the suppression of the master regulators of mitochondrial biogenesis and function, PGC1 α and PGC1 β .

The telomere–p53–mitochondrion model of ageing integrates many factors that have been shown to be important in the ageing process. On the genomic level, it accounts for ageing driven by DNA damage. This damage can stem from telomere shortening or from a decrease in the expression of genes that mediate DNA stability and DNA repair. Second, the model accounts for ageing syndromes documented in mice with hyperactive *Tp53* alleles and mouse models that show increased DNA damage owing to mutations in *Terc*, *Tert*, the DNA repair genes *Ku80* (also known as *Xrcc5*) and breast cancer 1 (*Brca1*), and *Zmpste24*, which encodes a metalloproteinase involved in lamin A maturation (lamin A is a crucial component of the nuclear envelope, and mutations of this metalloproteinase lead to premature ageing)^{104,105}. Finally, the model accounts for ageing phenotypes that stem from mitochondrial dysfunction,

as mice lacking PGC1 α , PGC1 β , BMI (a negative regulator of p16 that is upregulated in many tissues) or FOXO develop accelerated tissue degeneration and mitochondrial dysfunction^{106–109}.

This model could also explain both the slow but progressive physiological decline and the precipitous nature of the ageing process (FIG. 3). Ensuing mitochondrial dysfunction sustains a feed-forward cycle of DNA damage and further mitochondrial dysfunction through the generation of DNA-damaging ROS and possibly other mitochondrion-derived factors, such as iron–sulphur (Fe–S) clusters and NADH/NAD. This boost in ROS production fuels a detrimental cycle of increased genotoxic damage, particularly to the G-rich sequences of telomeres, followed by sustained activation of p53, further mitochondrial decline, more ROS generation, and so on^{110,111}. Increased ROS levels also damage other cellular components, including mtDNA, which further sustains this feed-forward spiral of damage by suppressing the expression of mtDNA-encoded genes for OXPHOS. Under conditions of severe nuclear or mtDNA damage, however, this cycle could be bypassed, and the premature ageing phenotype could be driven by increased apoptosis across different tissues, as reported in mutator mice (which carry a mutant form of Poly; see above)^{38,39}.

The continuous, escalating nature of this cycle could explain the differential effect of p53 on ageing in response to varying degrees of DNA damage. Under low levels of genotoxic stress, p53 induces the expression of antioxidants, thereby favouring cell survival. By contrast, increasing levels of DNA damage promote the expression of pro-oxidants, which further promote cell damage¹¹². Similarly, p53 has been shown to promote mitochondrial function and biogenesis in wild-type mice or in cells with low levels of p53, but under conditions of genotoxic stress p53 is associated with impaired mitochondrial function^{19,113–115}. There is also evidence that p53 either does not change lifespan (as demonstrated in mice with a hypomorphic *Mdm2* allele and in transgenic mice carrying an extra copy of the wild-type *Tp53* locus) or delays ageing (which was shown in mice carrying one extra copy of *Tp53* and increased copies of the tumour suppressor *Arf* (also known as *Cdkn2a*)^{116,117}. Furthermore, studies in worms have demonstrated that the p53 orthologue CEP-1 can extend or decrease lifespan depending on the degree of mitochondrial impairment, which indicates that the dichotomous role of p53 might be preserved during evolution¹¹⁸.




Figure 3 | A unified theory of ageing. In this model, increased DNA damage (for example, owing to telomere attrition, impaired DNA repair and increased reactive oxygen species (ROS) levels) activates p53, and increasing levels of p53 ultimately lead to compromised mitochondrial function through the repression of PPAR γ co-activator 1 α (PGC1 α) and PGC1 β (which promote mitochondrial biogenesis). This p53-mediated mitochondrial dysfunction triggers a cycle of DNA damage (by affecting the production of ROS, iron–sulphur (Fe–S) clusters and NADH/NAD), which in turn leads to further p53 activation and mitochondrial compromise. This feed-forward loop could also account for the divergent and opposite effects of many players in the ageing process. Under mild stress conditions, several components depicted here (p53, mitochondria and AMP-activated protein kinase (AMPK)) have been shown to preserve cellular function but to promote cellular ageing under more severe stress conditions (see text). The interplay between p53 and other pathways that have been implicated in ageing is also indicated. p53 represses the activity of the insulin and insulin-like growth factor 1 (IGF1) pathway and the mammalian target of rapamycin (mTOR) pathway and activates AMPK. How the altered activity of these pathways modifies mitochondrial function and the ageing process in the setting of increased DNA damage is not clear. Other p53-dependent and p53-independent pathways might cooperate in inducing mitochondrial dysfunction. For example, BMI1 indirectly inhibits p53 activation, and BMI1 loss upregulates p16 expression, which increases p53 activity indirectly (dashed arrow) by interacting with MDM2, the negative regulator of p53 (not shown). BMI1 has also been shown to induce mitochondrial dysfunction (probably indirectly). In addition, loss of sirtuins may contribute to mitochondrial dysfunction, as active sirtuin 1 (SIRT1) decreases p53 activity, and loss of SIRT1 promotes p53 activation and its downstream functions. SIRT1 also activates PGC1 α and thereby boosts mitochondrial biogenesis. The consequences of mitochondrial dysfunction are, when mild, functional impairment (for example, decreased ATP generation and β -oxidation) without cell loss. However, under increased stress conditions, mitochondrial dysfunction leads to functional impairment and concomitant loss of parenchymal mass owing to increased apoptosis and senescence.

In the presented model, mild DNA damage and mild or moderate levels of p53 activation would allow repair and maintenance of cellular function, whereas excessive DNA damage and p53 activation would eliminate cells that are not fit to survive or carry too much damage. These genetic findings also highlight the differential effects of mitochondrial function on lifespan observed in worms, flies and mice and indicate that the functional consequences of mitochondrial impairment could also depend on the activity levels of p53. The mild inhibition of mitochondrial respiration could activate longevity pathways (including those governed by p53), whereas more pronounced impairment of mitochondrial respiration

with additional defects in biochemical processes, such as β -oxidation, could trigger a lifespan-shortening programme.

How p53 switches from a pro-survival to a pro-ageing protein is largely unknown, but the intersection of p53 with the insulin and IGF1, mTOR and AMPK pathways might provide some clues²⁸. p53 suppresses the insulin and IGF1 pathway and the mTOR pathway through direct transcriptional upregulation of the negative regulators phosphatase and tensin homologue (PTEN), IGF1-binding protein 3 (IGF1BP3) and tuberous sclerosis protein 2 (TSC2; also known as tuberin), and p53 activates AMPK through direct transcriptional upregulation of its β -subunit²⁸. Interestingly, prematurely

aged mice with increased levels of DNA damage or with p53 hyperactivation show suppression of the insulin and IGF1 pathway and the mTOR pathway^{119,120}. These paradoxical findings can be reconciled by the view that the activation of these pathways represents a compensatory mechanism to maintain and prolong lifespan in the setting of ongoing DNA damage¹²⁰. However, it is not clear whether the activation of these longevity pathways in the context of DNA damage leads to the same transcriptional and cellular changes as seen in long-lived carriers of mutations in these pathways. For example, the prolonged activation of AMPK seen under energy stress leads to p53-dependent cellular senescence and apoptosis, which indicates that AMPK activation can accelerate cellular ageing under specific conditions⁵². Similarly, IGF1 concentration decreases with age, and this has been linked to functional decline in different stem cells¹²¹. These findings further support the notion that the effects of classical ageing pathways might be context dependent.

The model presented here acknowledges the existence of other, yet to be identified pathways that are involved in mediating mitochondrial and metabolic compromise, as p53 deficiency in mice with dysfunctional telomeres only partially restores PGC levels and ameliorates mitochondrial defects. Other p53 family members are prime candidates, in particular p63, which has been shown to be involved in organismal ageing and cellular senescence^{122,123}. Sirtuins may also have a role, as they associate with telomeres and regulate p53 and PGC1 α ¹²⁴. Indeed, SIRT1 activity has been found to decrease in aged tissues, and this might contribute to the increased p53 activity and suppressed PGC1 α activity seen in aged mouse and human tissues^{7,106}. However, recent reports have questioned the relevance of SIRT1 in lifespan regulation¹²⁵, which emphasizes the need for studies that focus on the role of sirtuins and their linkage to this axis in ageing and age-related pathologies. Another potential candidate is the BMI-p16 pathway, as it is highly implicated in ageing, and loss of BMI impairs mitochondrial function¹⁰⁷. Finally, p21-dependent signalling has been suggested to induce mitochondrial dysfunction in cultured human fibroblasts with critically short telomeres, although it should be noted that fibroblasts depend less on mitochondria and OXPHOS for ATP production and mainly use glycolysis to generate ATP⁸⁶. In this context, it is important to note here that telomere-dysfunctional yeast display increased expression of OXPHOS genes and proliferation of

mitochondria (although the functionality of the mitochondria was not tested), and senescent fibroblasts with dysfunctional telomeres have been reported to have increased mitochondrial biogenesis^{126,127}. These studies highlight not only the cell-specific effects of telomere dysfunction on mitochondrial biology but also the differences between mice and yeast, which might be related to growth conditions and yeast-specific regulation after telomere dysfunction.

In this model, the cellular phenotypes induced by mitochondrial dysfunction would range from functional impairment (for example, decreased ATP generation) to classical cellular phenotypes of growth arrest, senescence and apoptosis. The link between impaired mitochondrial function and cellular senescence has been demonstrated *in vitro*: decreasing the expression of Rieske Fe-S protein (RISP) of complex III or pharmacological inhibition of the electron transport chain and OXPHOS are sufficient to trigger senescence¹²⁸. The combined effects of these non-exclusive phenotypes would include cellular and tissue compromise and functional failure.

“ Deciphering these ageing networks could advance the development of therapeutic strategies ”

Conclusion

The integrated model of ageing presented in this Opinion article focuses on the intersection of DNA damage and metabolic pathways and how they might converge on a common effector, mitochondria, to drive ageing. Although this model centres on mitochondria, other important effectors of ageing, such as dysregulated autophagy, translation and protein folding, no doubt conspire to bring about and/or reinforce the ageing process¹²⁹⁻¹³¹. It remains to be established whether and how these different effectors are commonly used by DNA damage and metabolic pathways to drive ageing. Similarly, how these effectors are interconnected merits further studies in different ageing model systems.

It is largely unclear how mitochondria, p53 and other players of the ageing process can both extend and shorten lifespan. It will be crucial to establish the molecular mechanisms that determine different outcomes, which may involve cell-type-specific actions of p53 and/or various isoforms of the p53 family members. In this regard, it will be essential to characterize what other mitochondrial

biochemical pathways (beyond ROS production and OXPHOS) are impaired and might contribute to cellular and organismal ageing.

Deciphering these ageing networks could yield biomarkers of ageing and advance the development of therapeutic strategies designed to rejuvenate both proliferating and quiescent tissues in the aged. These therapeutic strategies might include: stabilizing telomeres through transient telomerase reactivation; attenuation of p53 activation or neutralization of specific p53 targets that are specifically involved in ageing; and enhancing PGC activity to promote mitochondrial biogenesis and function. Along these lines, a small molecule activator of telomerase has been reported to prolong healthspan in female mice without increasing the risk of cancer¹³². Moreover, PGC1 α overexpression in skeletal muscle ameliorates age-associated decline of muscular function in wild-type mice¹³³. Similarly, other interventions known to improve mitochondrial biogenesis and function, such as physical activity or administration of resveratrol (which is a putative sirtuin activator), have been shown to improve age-associated decline^{134,135}. It is intriguing that sirtuins can deacetylate p53 (which decreases its activity) and PGCs (which increases their activity), thereby differentially modulating two key components in the pathway that connects DNA damage signalling and mitochondrial decline. Beyond ageing, recent studies have also uncovered the importance of the telomere-p53-mitochondrion axis for cancer, which suggests that this pathway could be targeted for cancer therapy¹³⁶.

The discovery of the molecular circuitry of ageing has positioned the field to develop rational strategies for ageing, a ‘disease’ with 100% penetrance and 100% mortality. Although it remains to be determined whether natural ageing can be blocked or even be reversed, as recently demonstrated in the premature ageing setting⁷³, therapeutic manipulation of this pathway may hold promise for the reduction of age-related diseases, which have become more prevalent with marked increases in life expectancy worldwide.

Ergün Sahin is at the Huffington Center On Aging and the Department of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.

Ronald A. DePinho is at the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

e-mails: esahin@bcm.edu; rdepinho@mdanderson.org

*doi:10.1038/nrm3352
Published online 16 May 2012*

- Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J. W. Ageing populations: the challenges ahead. *Lancet* **374**, 1196–1208 (2009).
- Kenyon, C., Chang, J., Gensch, E., Rudner, A. & Tabtiang, R. A. *C. elegans* mutant that lives twice as long as wild type. *Nature* **366**, 461–464 (1993).
- Kenyon, C. J. The genetics of ageing. *Nature* **464**, 504–512 (2010).
- Deelen, J. *et al.* Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. *Age (Dordr.)* **24** Nov 2011 (doi:10.1007/s11357-011-9340-3).
- Ziv, E. & Hu, D. Genetic variation in insulin/IGF-1 signaling pathways and longevity. *Ageing Res. Rev.* **10**, 201–204 (2011).
- Guarente, L. Mitochondria — a nexus for aging, calorie restriction, and sirtuins? *Cell* **132**, 171–176 (2008).
- Sahin, E. & Depinho, R. A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature* **464**, 520–528 (2010).
- Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. *Exp. Cell Res.* **25**, 585–621 (1961).
- Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. *Nature* **345**, 458–460 (1990).
- Allsopp, R. C. *et al.* Telomere length predicts replicative capacity of human fibroblasts. *Proc. Natl Acad. Sci. USA* **89**, 10114–10118 (1992).
- Hastie, N. D. *et al.* Telomere reduction in human colorectal carcinoma and with ageing. *Nature* **346**, 866–868 (1990).
- Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? *Mutat. Res.* **256**, 271–282 (1991).
- Vaziri, H. & Benichou, S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. *Exp. Gerontol.* **31**, 295–301 (1996).
- Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. *Curr. Biol.* **13**, 1549–1556 (2003).
- Chin, L. *et al.* p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell* **97**, 527–538 (1999).
- Wong, K. K. *et al.* Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. *Nature* **421**, 643–648 (2003).
- Ferron, S. *et al.* Telomere shortening and chromosomal instability abrogates proliferation of adult but not embryonic neural stem cells. *Development* **131**, 4059–4070 (2004).
- Flores, I. & Blasco, M. A. A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. *PLoS ONE* **4**, e4934 (2009).
- Sahin, E. *et al.* Telomere dysfunction induces metabolic and mitochondrial compromise. *Nature* **470**, 359–365 (2011).
- Harrison, D. E. *et al.* Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* **460**, 392–395 (2009).
- Chiachiera, F. & Simone, C. The AMPK—FoxO3A axis as a target for cancer treatment. *Cell Cycle* **9**, 1091–1096 (2010).
- Canto, C. & Auwerx, J. PGC-1 α , SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Curr. Opin. Lipidol.* **20**, 98–105 (2009).
- Daitoku, H., Yamagata, K., Matsuzaki, H., Hatta, M. & Fukamizu, A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. *Diabetes* **52**, 642–649 (2003).
- Olmos, Y. *et al.* Mutual dependence of Foxo3a and PGC-1 α in the induction of oxidative stress genes. *J. Biol. Chem.* **284**, 14476–14484 (2009).
- Puigserver, P. *et al.* Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 α interaction. *Nature* **423**, 550–555 (2003).
- Luo, J. *et al.* Negative control of p53 by Sir2 α promotes cell survival under stress. *Cell* **107**, 137–148 (2001).
- Vaziri, H. *et al.* hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* **107**, 149–159 (2001).
- Feng, Z. & Levine, A. J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. *Trends Cell Biol.* **20**, 427–434 (2010).
- Haigis, M. C. & Yankner, B. A. The aging stress response. *Mol. Cell* **40**, 333–344 (2010).
- Sadagurski, M. *et al.* IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. *J. Clin. Invest.* **121**, 4070–4081 (2011).
- Brown-Borg, H. M., Johnson, W. T. & Rakoczy, S. G. Expression of oxidative phosphorylation components in mitochondria of long-living Ames dwarf mice. *Age (Dordr.)* **34**, 43–57 (2011).
- Tothova, Z. *et al.* FoxOs are critical mediators of hematopoietic stem cell resistance to physiological oxidative stress. *Cell* **128**, 325–339 (2007).
- Renault, V. M. *et al.* FoxO3 regulates neural stem cell homeostasis. *Cell Stem Cell* **5**, 527–539 (2009).
- Paik, J. H. *et al.* FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. *Cell Stem Cell* **5**, 540–553 (2009).
- Zid, B. M. *et al.* 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in *Drosophila*. *Cell* **139**, 149–160 (2009).
- Selman, C. *et al.* Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* **326**, 140–144 (2009).
- Canto, C. *et al.* AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature* **458**, 1056–1060 (2009).
- Trifunovic, A. *et al.* Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* **429**, 417–423 (2004).
- Kujoth, G. C. *et al.* Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science* **309**, 481–484 (2005).
- Dai, D. F. *et al.* Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. *Circulation* **119**, 2789–2797 (2009).
- Dai, D. F. *et al.* Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. *Aging Cell* **9**, 536–544 (2010).
- Perez, V. I. *et al.* Is the oxidative stress theory of aging dead? *Biochim. Biophys. Acta* **1790**, 1005–1014 (2009).
- Hekimi, S., Lapointe, J. & Wen, Y. Taking a “good” look at free radicals in the aging process. *Trends Cell Biol.* **21**, 569–576 (2011).
- Safdar, A. *et al.* Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. *Proc. Natl Acad. Sci. USA* **108**, 4135–4140 (2011).
- Dillin, A. *et al.* Rates of behavior and aging specified by mitochondrial function during development. *Science* **298**, 2398–2401 (2002).
- Lee, S. S. *et al.* A systematic RNAi screen identifies a critical role for mitochondria in *C. elegans* longevity. *Nature Genet.* **35**, 40–48 (2003).
- Kirchman, P. A., Kim, S., Lai, C. Y. & Jazwinski, S. M. Interorganelle signaling is a determinant of longevity in *Saccharomyces cerevisiae*. *Genetics* **152**, 179–190 (1999).
- Dell’agnello, C. *et al.* Increased longevity and refractoriness to Ca²⁺-dependent neurodegeneration in Surf1 knockout mice. *Hum. Mol. Genet.* **16**, 431–444 (2007).
- Liu, X. *et al.* Evolutionary conservation of the *clk-1*-dependent mechanism of longevity: loss of *mclk1* increases cellular fitness and lifespan in mice. *Genes Dev.* **19**, 2424–2434 (2005).
- Vigneron, A. & Voudsen, K. H. p53, ROS and senescence in the control of aging. *Aging (Albany NY)* **2**, 471–474 (2010).
- Sung, J. Y., Woo, C. H., Kang, Y. J., Lee, K. Y. & Choi, H. C. AMPK induces vascular smooth muscle cell senescence via LKB1 dependent pathway. *Biochem. Biophys. Res. Commun.* **413**, 143–148 (2011).
- Jones, R. G. *et al.* AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. *Mol. Cell* **18**, 285–293 (2005).
- Blackburn, E. H. Switching and signaling at the telomere. *Cell* **106**, 661–675 (2001).
- Shay, J. W. & Wright, W. E. Hallmarks of telomeres in ageing research. *J. Pathol.* **211**, 114–123 (2007).
- Chan, S. R. & Blackburn, E. H. Telomeres and telomerase. *Phil. Trans. R. Soc. Lond. B* **359**, 109–121 (2004).
- Kim, N. W. *et al.* Specific association of human telomerase activity with immortal cells and cancer. *Science* **266**, 2011–2015 (1994).
- Bodnar, A. G. *et al.* Extension of life-span by introduction of telomerase into normal human cells. *Science* **279**, 349–352 (1998).
- Aikata, H. *et al.* Telomere reduction in human liver tissues with age and chronic inflammation. *Exp. Cell Res.* **256**, 578–582 (2000).
- Aubert, G. & Lansdorp, P. M. Telomeres and aging. *Physiol. Rev.* **88**, 557–579 (2008).
- Chimenti, C. *et al.* Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. *Circ. Res.* **93**, 604–613 (2003).
- Chen, J. Hematopoietic stem cell development, aging and functional failure. *Int. J. Hematol.* **94**, 3–10 (2011).
- Blasco, M. A. Telomeres and human disease: ageing, cancer and beyond. *Nature Rev. Genet.* **6**, 611–622 (2005).
- Calado, R. T. & Young, N. S. Telomere diseases. *N. Engl. J. Med.* **361**, 2353–2365 (2009).
- Martin, G. M. Genetic modulation of senescent phenotypes in *Homo sapiens*. *Cell* **120**, 523–532 (2005).
- Armanios, M. Syndromes of telomere shortening. *Annu. Rev. Genom. Hum. Genet.* **10**, 45–61 (2009).
- Flores, I. *et al.* The longest telomeres: a general signature of adult stem cell compartments. *Genes Dev.* **22**, 654–667 (2008).
- Hewitt, G. *et al.* Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. *Nature Commun.* **3**, 708 (2012).
- Hemann, M. T., Strong, M. A., Hao, L. Y. & Greider, C. W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell* **107**, 67–77 (2001).
- Hao, L. Y. *et al.* Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. *Cell* **123**, 1121–1131 (2005).
- Tomas-Loba, A. *et al.* Telomerase reverse transcriptase delays aging in cancer-resistant mice. *Cell* **135**, 609–622 (2008).
- Lee, H. W. *et al.* Essential role of mouse telomerase in highly proliferative organs. *Nature* **392**, 569–574 (1998).
- Rudolph, K. L. *et al.* Longevity, stress response, and cancer in aging telomerase-deficient mice. *Cell* **96**, 701–712 (1999).
- Du, X. *et al.* Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. *Mol. Cell Biol.* **24**, 8437–8446 (2004).
- Chang, S. *et al.* Essential role of limiting telomeres in the pathogenesis of Werner syndrome. *Nature Genet.* **36**, 877–882 (2004).
- Jaskelioff, M. *et al.* Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature* **469**, 102–106 (2011).
- Vulliamy, T. J. & Dokal, I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. *Biochimie* **90**, 122–130 (2008).
- Muftuoglu, M. *et al.* The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. *Hum. Genet.* **124**, 369–377 (2008).
- Perlman, S., Becker-Catania, S. & Gatti, R. A. Ataxia-telangiectasia: diagnosis and treatment. *Semin. Pediatr. Neurol.* **10**, 175–182 (2003).
- Sharpless, N. E. & DePinho, R. A. Telomeres, stem cells, senescence, and cancer. *J. Clin. Invest.* **113**, 160–168 (2004).
- Choudhury, A. R. *et al.* *Cdkn1a* deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. *Nature Genet.* **39**, 99–105 (2007).
- Leri, A. *et al.* Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. *EMBO J.* **22**, 131–139 (2003).
- Lee, J. W., Harrigan, J., Opreško, P. L. & Bohr, V. A. Pathways and functions of the Werner syndrome protein. *Mech. Ageing Dev.* **126**, 79–86 (2005).
- Yang, D. Q., Halaby, M. J., Li, Y., Hibma, J. C. & Burn, P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. *Drug Discov. Today* **16**, 332–338 (2011).
- Basel-Vanagaite, L. *et al.* Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by *TERT* mutations. *Haematologica* **93**, 943–944 (2008).
- Mercer, J. R. *et al.* DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. *Circ. Res.* **107**, 1021–1031 (2010).

86. Passos, J. F. *et al.* Feedback between p21 and reactive oxygen production is necessary for cell senescence. *Mol. Syst. Biol.* **6**, 347 (2010).
87. Kovalenko, O. A. *et al.* A mutant telomerase defective in nuclear-cytoplasmic shuttling fails to immortalize cells and is associated with mitochondrial dysfunction. *Aging Cell* **9**, 203–219 (2010).
88. Haendeler, J. *et al.* Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. *Arterioscler. Thromb. Vasc. Biol.* **29**, 929–935 (2009).
89. Guo, N. *et al.* Short telomeres compromise β -cell signaling and survival. *PLoS ONE* **6**, e17858 (2011).
90. Sarin, K. Y. *et al.* Conditional telomerase induction causes proliferation of hair follicle stem cells. *Nature* **436**, 1048–1052 (2005).
91. Lee, J. *et al.* TERT promotes cellular and organismal survival independently of telomerase activity. *Oncogene* **27**, 3754–3760 (2008).
92. Choi, J. *et al.* TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. *PLoS Genet.* **4**, e10 (2008).
93. Cong, Y. & Shay, J. W. Actions of human telomerase beyond telomeres. *Cell Res.* **18**, 725–732 (2008).
94. Flores, I., Cayuela, M. L. & Blasco, M. A. Effects of telomerase and telomere length on epidermal stem cell behavior. *Science* **309**, 1253–1256 (2005).
95. Vidal-Cardenas, S. L. & Greider, C. W. Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase. *Nucleic Acids Res.* **38**, 60–71 (2010).
96. Santos, J. H., Meyer, J. N., Skovvaga, M., Annab, L. A. & Van Houten, B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. *Aging Cell* **3**, 399–411 (2004).
97. Sharma, N. K. *et al.* Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. *Nucleic Acids Res.* **40**, 712–725 (2011).
98. Ahmed, S. *et al.* Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. *J. Cell Sci.* **121**, 1046–1053 (2008).
99. Park, J. I. *et al.* Telomerase modulates Wnt signalling by association with target gene chromatin. *Nature* **460**, 66–72 (2009).
100. Strong, M. A. *et al.* Phenotypes in mTERT^{+/+} and mTERT^{-/-} mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. *Mol. Cell. Biol.* **31**, 2369–2379 (2011).
101. Patel, A. Y., McDonald, T. M., Spears, L. D., Ching, J. K. & Fisher, J. S. Ataxia telangiectasia mutated influences cytochrome c oxidase activity. *Biochem. Biophys. Res. Commun.* **405**, 599–603 (2011).
102. Ambrose, M., Goldstine, J. V. & Gatti, R. A. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. *Hum. Mol. Genet.* **16**, 2154–2164 (2007).
103. Pallardo, F. V. *et al.* Mitochondrial dysfunction in some oxidative stress-related genetic diseases: ataxia-telangiectasia, down syndrome, Fanconi anaemia and Werner syndrome. *Biogerontology* **11**, 401–419 (2010).
104. Varela, I. *et al.* Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. *Nature* **437**, 564–568 (2005).
105. Lombard, D. B. *et al.* DNA repair, genome stability, and aging. *Cell* **120**, 497–512 (2005).
106. Wenz, T. Mitochondria and PGC-1 α in aging and age-associated diseases. *J. Aging Res.* **2011**, 810619 (2011).
107. Liu, J. *et al.* Bmi1 regulates mitochondrial function and the DNA damage response pathway. *Nature* **459**, 387–392 (2009).
108. Salih, D. A. & Brunet, A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. *Curr. Opin. Cell Biol.* **20**, 126–136 (2008).
109. Kim, W. Y. & Sharpless, N. E. The regulation of INK4/ARF in cancer and aging. *Cell* **127**, 265–275 (2006).
110. von Zglinicki, T. Oxidative stress shortens telomeres. *Trends Biochem. Sci.* **27**, 339–344 (2002).
111. Passos, J. F., Saretzki, G. & von Zglinicki, T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? *Nucleic Acids Res.* **35**, 7505–7513 (2007).
112. Sablina, A. A. *et al.* The antioxidant function of the p53 tumor suppressor. *Nature Med.* **11**, 1306–1313 (2005).
113. Matoba, S. *et al.* p53 regulates mitochondrial respiration. *Science* **312**, 1650–1653 (2006).
114. Bae, B. I. *et al.* p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. *Neuron* **47**, 29–41 (2005).
115. Saleem, A., Adhithy, P. J. & Hood, D. A. Role of p53 in mitochondrial biogenesis and apoptosis in skeletal muscle. *Physiol. Genom.* **37**, 58–66 (2009).
116. Mendrysa, S. M. *et al.* Tumor suppression and normal aging in mice with constitutively high p53 activity. *Genes Dev.* **20**, 16–21 (2006).
117. Matheu, A. *et al.* Delayed ageing through damage protection by the Arf/p53 pathway. *Nature* **448**, 375–379 (2007).
118. Ventura, N. *et al.* p53/CEP-1 increases or decreases lifespan, depending on level of mitochondrial bioenergetic stress. *Aging Cell* **8**, 380–393 (2009).
119. Niedernhofer, L. J. *et al.* A new progeroid syndrome reveals that genotoxic stress suppresses the somatotropic axis. *Nature* **444**, 1038–1043 (2006).
120. Hinkal, G. & Donehower, L. A. How does suppression of IGF-1 signaling by DNA damage affect aging and longevity? *Mech. Ageing Dev.* **129**, 243–253 (2008).
121. Devin, J. K. & Young, P. P. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. *Curr. Opin. Investig. Drugs* **9**, 983–992 (2008).
122. Keyes, W. M. & Mills, A. A. p63: a new link between senescence and aging. *Cell Cycle* **5**, 260–265 (2006).
123. Su, X. & Flores, E. R. Tap63: the fountain of youth. *Aging (Albany NY)* **1**, 866–869 (2009).
124. Finkel, T., Deng, C. X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. *Nature* **460**, 587–591 (2009).
125. Burnett, C. *et al.* Absence of effects of Sir2 overexpression on lifespan in *C. elegans* and *Drosophila*. *Nature* **477**, 482–485 (2011).
126. Passos, J. F. *et al.* Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. *PLoS Biol.* **5**, e110 (2007).
127. Nautiyal, S., DeRisi, J. L. & Blackburn, E. H. The genome-wide expression response to telomerase deletion in *Saccharomyces cerevisiae*. *Proc. Natl Acad. Sci. USA* **99**, 9316–9321 (2002).
128. Moiseeva, O., Bourdeau, V., Roux, A., Deschenes-Simard, X. & Ferbeyre, G. Mitochondrial dysfunction contributes to oncogene-induced senescence. *Mol. Cell. Biol.* **29**, 4495–4507 (2009).
129. Rubinsztein, D. C., Marino, G. & Kroemer, G. Autophagy and aging. *Cell* **146**, 682–695 (2011).
130. McCormick, M. A., Tsai, S. Y. & Kennedy, B. K. TOR and ageing: a complex pathway for a complex process. *Phil. Trans. R. Soc. B* **366**, 17–27 (2011).
131. Hartl, F. U., Bracher, A. & Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. *Nature* **475**, 324–332 (2011).
132. de Jesus, B. B. *et al.* The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. *Aging Cell* **10**, 604–621 (2011).
133. Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M. & Moraes, C. T. Increased muscle PGC-1 α expression protects from sarcopenia and metabolic disease during aging. *Proc. Natl Acad. Sci. USA* **106**, 20405–20410 (2009).
134. Little, J. P., Safdar, A., Bishop, D., Tarnopolsky, M. A. & Gibala, M. J. An acute bout of high-intensity interval training increases the nuclear abundance of PGC-1 α and activates mitochondrial biogenesis in human skeletal muscle. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **300**, R1303–R1310 (2011).
135. Timmers, S. *et al.* Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. *Cell Metab.* **14**, 612–622 (2011).
136. Hu, J. *et al.* Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. *Cell* **148**, 651–663 (2012).
137. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nature Rev. Mol. Cell Biol.* **12**, 21–35 (2011).
138. Hardie, D. G. Signal transduction: How cells sense energy. *Nature* **472**, 176–177 (2011).

Acknowledgements

The authors apologize to all their colleagues whose work could not be cited. Part of the work described in this article was supported by a fellowship from the Deutsche Forschungsgemeinschaft (to E.S.) and by R01 and U01 grants from the US National Institutes of Health (NIH) National Cancer Institute and the Robert A. and Renee E. Belfer Foundation. R.A.D. was supported by an Ellison Foundation for Medical Research Senior Scholar and an American Cancer Society Research Professor award.

Competing interests statement

The authors declare no competing financial interests.

FURTHER INFORMATION

Ronald A. DePinho's homepage: <http://www.mdanderson.org/about-us/president-ronald-depinho-m-d/index.html>.

ALL LINKS ARE ACTIVE IN THE ONLINE PDF